Skip to content

Study of therapeutic effect of sitagliptin

Study of the effect of dipeptidyl peptidase 4 inhibitors on the improvement rate and prognosis of diabetic patients with Covid-19

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200420047147N2
Enrollment
70
Registered
2022-03-07
Start date
2022-03-11
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19 ,virus identified

Interventions

Intervention 1: Intervention group: Diabetic patients with Covid-19 will be given 100 mg of sitgliptin (50 mg every 12 hours, Dr. Abidi Pharmaceuticals, Iran) daily in addition to the medications used

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who have been diagnosed with Covid 19 based on CT scan or PCR. Patients with fasting blood sugar above 100 at the time of referral Patients with previous diagnosis of diabetes and under treatment Study and accept consent to participate in the study Patients over 18 years of age

Exclusion criteria

Exclusion criteria: Acute renal failure, chronic renal failure with stage 4,5 Acute and chronic liver failure History of immunodeficiency diseases, using immunodeficiency drugs Pregnancy and breastfeeding Patients who are admitted to the intensive care unit upon arrival Patients with contraindications to cytagliptin (pancreatitis and its history, diabetic gastroparesis, history of severe drug allergy)

Design outcomes

Primary

MeasureTime frame
O2 saturation without mask. Timepoint: Daily. Method of measurement: Thermometer.;Fasting blood suger. Timepoint: Daily, From admission to discharge time. Method of measurement: Glucometer.;Covid-19 infection. Timepoint: At the beginning of the hospital admission. Method of measurement: Covid RT-PCR test.;Disease severity. Timepoint: At the beginning and end of intervention. Method of measurement: Based on protocol and clinical symptoms.;Cbc diff. Timepoint: every other day in between from the beginning of hospitalization until discharge. Method of measurement: labratory.

Secondary

MeasureTime frame
Hospitalization duration. Timepoint: discharge time. Method of measurement: clinical record.;Death. Timepoint: at the end of study. Method of measurement: medical record.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sadidi

Artesh University of Medical Sciences

m100idi@yahoo.com+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026